A5090464803- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
- Gastrointestinal Tumor Research and Treatment
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Cancer Cells and Metastasis
- Multiple and Secondary Primary Cancers
- Neuroendocrine Tumor Research Advances
- Melanoma and MAPK Pathways
Hospital General Universitario Gregorio Marañón
2016-2025
Universidad Complutense de Madrid
2013-2025
Hospital Universitario HM Sanchinarro
2024
HM Hospitales
2024
Sociedad Española de Medicina Interna
2012
Sociedad Española de Oncología Médica
2012
Hospital Del Mar
2009
Hospital Universitario de Móstoles
2005
Hospital Universitario La Paz
2004
Hospital Provincial de Conxo
1996
Patients with metastatic colorectal cancer the BRAF V600E mutation have a poor prognosis, median overall survival of 4 to 6 months after failure initial therapy. Inhibition alone has limited activity because pathway reactivation through epidermal growth factor receptor signaling.
BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan FOLFIRI in patients BRAFV600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, (ENCO/BINI/CETUX; triplet) and (ENCO/CETUX; doublet) regimens improved overall survival (OS) objective response rate (ORR; by blinded central review) standard care. The purpose this analysis was to report...
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab patients microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment fluoropyrimidine, oxaliplatin, irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose the first-line therapy cohort from phase II 142 study. PATIENTS AND METHODS Patients no prior setting for...
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
Background Programmed death-1 (PD-1) inhibitors, including nivolumab, have demonstrated long-term survival benefit in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC). PD-1 and lymphocyte-activation gene 3 (LAG-3) are distinct immune checkpoints that often co-expressed on tumor-infiltrating lymphocytes contribute to tumor-mediated T-cell dysfunction. Relatlimab is a LAG-3 inhibitor has efficacy...
11 Background: In the phase 2 CheckMate 142 trial, nivolumab plus low-dose ipilimumab provided robust and durable clinical benefit was well tolerated as first-line therapy for microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) (Lenz et al. Ann Oncol 2018;29:LBA18). Longer follow-up data will be presented. Methods: Patients with MSI-H/dMMR mCRC no prior treatment disease received 3 mg/kg every weeks 1 6 until progression or...
The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, demonstrated HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. aim of this was to explore potential activity safety capecitabine, oxaliplatin (XELOX) patients with HER-2 positive cancer. We conducted a multicentre, prospective, non-randomised, non-controlled, open-label national (Spanish)...
We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) capecitabine (C-B) in untreated patients unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination cytotoxic chemotherapies.From 29 April 2016 March 2017, 153 randomly assigned (1:1) either TT-B (N = 77) or C-B 76). The primary end point was progression-free survival (PFS). PFS analysis performed...
Abstract Learning Objectives After completing this course, the reader will be able to: Use patient age as only one consideration, along with tumor status and comorbidities, in deciding on treatment strategies for elderly colorectal cancer patients.Obtain apply information regarding medical, functional, mental, social of patients order to make appropriate therapeutic decisions. CME This article is available continuing medical education credit at CME.TheOncologist.com Purpose. To analyze...
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73-0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association RAS/RAF mutation status and anatomical location primary CRC tumour (left right) efficacy parameters.Patient tissue was classified as BRAF mutant, KRAS/NRAS (RAS) or RAS/BRAF wild-type. Left-CRC defined splenic flexure,...
// Xandra García-González 1,* , Lucía Cortejoso María I. García 1 Pilar García-Alfonso 2 Luis Robles 3 Cristina Grávalos Eva González-Haba Pellicer Marta Sanjurjo and A. López-Fernández Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Madrid, Spain Medical Oncology, Doce Octubre, * These authors contributed equally to the manuscript Correspondence: López-Fernández, email: Keywords : Flouropyrimidine, toxicity, chemotherapy,...
Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if addition of veliparib, concurrent to FOLFIRI, improves in patients with previously untreated mCRC. This study compared veliparib (200 mg BID for 7 days each 14-day cycle) placebo, FOLFIRI. Bevacizumab was allowed both arms. The primary endpoint progression-free (PFS). Patients were randomised receive (n = 65) or placebo combination Median PFS 12 vs 11 months (veliparib placebo) [HR 0.94 (95% CI: 0.60, 1.48)]. OS 25 27...
4001 Background: BEACON CRC is a randomized, phase 3 study which evaluated the triplet of encorafenib (ENCO) + binimetinib (BINI) cetuximab (CETUX) and doublet ENCO CETUX vs. investigator’s choice irinotecan or FOLFIRI in patients (pts) with BRAFV600E metastatic colorectal cancer (mCRC) whose disease had progressed after 1-2 prior regimens setting. Primary endpoints were overall survival (OS) objective response rate (ORR; by blinded central review) for vs control. In previous interim...
Purpose5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets as first-line therapy for metastatic colorectal cancer, but not widely used because of concerns about toxicity and lack predictive biomarkers. This study was designed to explore the role circulating tumour cell (CTC) count a biomarker select patients with FOLFOXIRI-bevacizumab.Patients methodsVISNÚ-1 multicentre, open-label, randomised, phase III in previously untreated,...
4040 Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI had robust, durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (median follow-up 13.8 months [mo; range, 9–19]; Lenz et al. Ann Oncol 2018;29:LBA18). Longer is presented here. Methods: Patients (pts) with no prior treatment metastatic disease received 3 mg/kg Q2W 1 Q6W until progression or discontinuation. The primary endpoint investigator-assessed (INV) objective response rate (ORR) per...
Abstract 5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors breast but their administration can produce serious even lethal toxicity. This toxicity is often related to partial or complete deficiency dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction clearance longer half-life 5-FU. It advisable determine if DPD exists before administering these drugs by genotyping DPYD gene...
3510 Background: NIVO ± IPI is approved in previously treated pts with MSI-H/dMMR mCRC the US, EU, and Japan, based on findings from phase 2 CheckMate 142 study (NCT02060188). NCCN guidelines include + as an initial therapy option for mCRC. Results a ~5-year follow-up cohorts 1–3 (C1–3) are reported here. Methods: In this non-randomized, multicohort study, were follows: C1 (2L+; 3 mg/kg Q2W), C2 1 Q3W [4 doses], followed by Q2W) C3 (1L; Q2W Q6W), until disease progression or unacceptable...